The Alport syndrome market is expected to witness significant growth over the coming years, driven by advancements in genetic diagnostics, increasing disease awareness, and the introduction of targeted therapies such as ELX-02 (Exaluren) (Eloxx Pharmaceuticals), Vonafexor (Enyo Pharma), BAY3401016 (Evotec and Bayer), Setanaxib (Asahi Kasei), Atrasentan (VANRAFIA) [Novartis (Chinook Therapeutics)], and others.